Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: Randomized controlled trial

American Journal of Hematology

Volumn 89, Issue 3, 2014, Pages 243-248

  Paul, Mical ^a,b   Ram, Ron ^a,b   Kugler, Eitan ^a   Farbman, Laura ^a,b   Peck, Anat ^a   Leibovici, Leonard ^a,b   Lahav, Meir ^a,b   Yeshurun, Moshe ^a,b   Shpilberg, Ofer ^a,b   Herscovici, Corina ^a,b   Wolach, Ofir ^a,b   Itchaki, Gilad ^a,b   Bar Natan, Michal ^a,b   Vidal, Liat ^a,b   Gafter Gvili, Anat ^a,b   Raanani, Pia ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER CHEMOTHERAPY; CENTRAL VENOUS CATHETER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEATH; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HOSPITAL PATIENT; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL MORTALITY; HUMANS; INFECTION; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INPATIENTS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; PATIENT SATISFACTION; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896849777     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23622     Document Type: Article

References (17)

1. Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008:CD003189.
2. Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198-4214.
3. Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400-411.
4. Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev 2012;6:CD008238.
5. NEUPOGEN® (filgrastim). Available from: http://www.amgen.com/medpro/products_neupogen.html. Last accessed 9 November, 2013.
6. Tanaka H, Okada Y, Kawagishi M, et al. Pharmacokinetics and pharmacodynamics of recombinant human granulocyte-colony stimulating factor after intravenous and subcutaneous administration in the rat. J Pharmacol Exp Ther 1989;251:1199-1203.
7. Lee KE, Mun YC, Nam SH, et al. A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors. Bone Marrow Transplant 2005;36:1027-1031.
8. Sugiura M, Yamamoto K, Sawada Y, et al. Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by recombinant granulocyte colony-stimulating factor (rhG-CSF): Comparison between intravenous and subcutaneous administration. Biol Pharm Bull 1997;20:684-689.
9. Wiczling P, Lowe P, Pigeolet E, et al. Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet 2009;48:817-826.
10. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
11. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
12. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332.
13. MD Anderson Cancer Center: Symptom Assessment Tools. http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/index.html.
14. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919.
15. Stroncek DF, Matthews CL, Follmann D, et al. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: Effects of route of administration and addition of dexamethasone. Transfusion 2002;42:597-602.
16. Rosenfeld CS, Sulecki M, Evans C, et al. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol 1991;19:273-277.
17. Bassler D, Montori VM, Briel M, et al. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol 2008;61:241-246.